We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oxonica | LSE:OXN | London | Ordinary Share | GB00B0D09P49 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.125 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMOXN RNS Number : 3159T Oxonica plc 03 June 2009 3 June 2009 Oxonica plc Annual Report & Accounts and Notice of Annual General Meeting The Company's Annual Report and Financial Statements for the year to 31 December 2008 were posted to our shareholders on Friday 8th May together with Notice of the Annual General Meeting, which is to be held in the Oxford Room, Begbroke Science Park, Yarnton, Oxford, at 11am on Thursday 18th June 2009. Copies are available for inspection free of charge at our registered office at 7 Begbroke Science Park, Sandy Lane, Yarnton, Kidlington, Oxfordshire, OX5 1PF and from our website at www.oxonica.com. For further information, please contact: Oxonica plc 01865 856 700 Kevin Matthews, Chief Executive Richard Clarke, Finance Director Panmure Gordon 020 7459 3600 Hugh Morgan Andrew Potts Notes to Editors About Oxonica plc - www.oxonica.com Oxonica (AIM: OXN.L) is a leading nanomaterials group with products already launched into international markets. Oxonica's mission is to focus on the commercialisation of innovative products using its expertise in the design and application of nanomaterials. Lead products include: * Envirox(TM) Fuel Borne Catalyst - a nanocatalyst improving fuel economy and reducing emissions * Optisol(TM) UV absorber - a photostable UV protection system designed to optimise the performance of quality sunscreens and anti-premature aging products The Group also generates licence and development revenue from activities in the clinical diagnostics and security markets. This information is provided by RNS The company news service from the London Stock Exchange END ACSILFSSREIVIIA
1 Year Oxonica Chart |
1 Month Oxonica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions